University of Wollongong

Research Online
Faculty of Engineering and Information
Sciences - Papers: Part B

Faculty of Engineering and Information
Sciences

2019

Two-dimensional solid-state array detectors: A technique for in vivo dose
verification in a variable effective area
Kananan Utitsarn
University of Wollongong, Lopburi Cancer Hospital, ku566@uowmail.edu.au

Giordano Biasi
University of Wollongong, gbiasi@uow.edu.au

Nauljun Stansook
University of Wollongong, Mahidol University, ns938@uowmail.edu.au

Z A. Alrowaili
University of Wollongong, Jouf University, zaa931@uowmail.edu.au

Marco Petasecca
University of Wollongong, marcop@uow.edu.au

See next page for additional authors

Follow this and additional works at: https://ro.uow.edu.au/eispapers1
Part of the Engineering Commons, and the Science and Technology Studies Commons

Recommended Citation
Utitsarn, Kananan; Biasi, Giordano; Stansook, Nauljun; Alrowaili, Z A.; Petasecca, Marco; Carolan, Martin
G.; Perevertaylo, Vladimir; Tome, Wolfgang; Kron, Tomas; Lerch, Michael L. F; and Rosenfeld, Anatoly B.,
"Two-dimensional solid-state array detectors: A technique for in vivo dose verification in a variable
effective area" (2019). Faculty of Engineering and Information Sciences - Papers: Part B. 3348.
https://ro.uow.edu.au/eispapers1/3348

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Two-dimensional solid-state array detectors: A technique for in vivo dose
verification in a variable effective area
Abstract
Purpose:We introduce a technique that employs a 2D detector in transmission mode (TM) to verify dose
maps at a depth of dmaxin Solid Water. TM measurements, when taken at a different surface‐to‐detector
distance (SDD), allow for the area at dmax(in which the dose map is calculated) to be
adjusted.Methods:We considered the detector prototype"MP512"(an array of 512 diode‐sensitive
volumes, 2 mm spatial resolution). Measurements in transmission mode were taken at SDDs in the range
from 0.3 to 24 cm. Dose mode (DM) measurements were made at dmaxin Solid Water. We considered
radiation fields in the range from 2x2cm2to 10x10 cm2, produced by 6 MV flattened photon beams;we
derived a relationship between DM and TM measurements as a function of SDD and field size. The
relationship was used to calculate, from TM measurements at 4 and 24 cm SDD, dose maps at dmaxin
fields of 1x1cm 2 and 4x4cm2, and in IMRT fields. Calculations were cross‐checked (gamma analysis)
with the treatment planning system and with measurements (MP512,films, ionization chamber).Results:In
the square fields, calculations agreed with measurements to within±2.36%. In the IMRT fields, using
acceptance criteria of 3%/3 mm, 2%/2 mm, 1%/1 mm, calculations had respective gamma passing rates
greater than 96.89%,90.50%, 62.20% (for a 4 cm SSD); and greater than 97.22%, 93.80%, 59.00% (for a24
cm SSD). Lower rates (1%/1 mm criterion) can be explained by submillimeter misalignments, dose
averaging in calculations, noise artifacts in film dosimetry. Conclusions:It is possible to perform TM
measurements at the SSD which produces the best fit between the area at dmaxin which the dose map is
calculated and the size of the monitored target.
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Purpose: We introduce a technique that employs a 2D detector in transmission
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mode (TM) to verify dose maps at a depth of dmax in Solid Water. TM measurements, when taken at a different surface‐to‐detector distance (SDD), allow for the
area at dmax (in which the dose map is calculated) to be adjusted.
Methods: We considered the detector prototype “MP512” (an array of 512 diode‐
sensitive volumes, 2 mm spatial resolution). Measurements in transmission mode
were taken at SDDs in the range from 0.3 to 24 cm. Dose mode (DM) measurements were made at dmax in Solid Water. We considered radiation ﬁelds in the
range from 2 × 2 cm2 to 10 × 10 cm2, produced by 6 MV ﬂattened photon beams;
we derived a relationship between DM and TM measurements as a function of
SDD and ﬁeld size. The relationship was used to calculate, from TM measurements
at 4 and 24 cm SDD, dose maps at dmax in ﬁelds of 1 × 1 cm2 and 4 × 4 cm2, and
in IMRT ﬁelds. Calculations were cross‐checked (gamma analysis) with the treatment
planning system and with measurements (MP512, ﬁlms, ionization chamber).
Results: In the square ﬁelds, calculations agreed with measurements to within
±2.36%. In the IMRT ﬁelds, using acceptance criteria of 3%/3 mm, 2%/2 mm, 1%/
1 mm, calculations had respective gamma passing rates greater than 96.89%,
90.50%, 62.20% (for a 4 cm SSD); and greater than 97.22%, 93.80%, 59.00% (for a
24 cm SSD). Lower rates (1%/1 mm criterion) can be explained by submillimeter
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misalignments, dose averaging in calculations, noise artifacts in ﬁlm dosimetry.
Conclusions: It is possible to perform TM measurements at the SSD which produces the best ﬁt between the area at dmax in which the dose map is calculated and
the size of the monitored target.
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2D solid‐state array detector, MP512, transmission detector, in vivo QA
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1 | INTRODUCTION
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2 | MATERIALS AND METHODS

Conformal radiotherapy techniques such as intensity‐modulated
radiotherapy (IMRT) and volumetric‐modulated arc radiotherapy
(VMAT)1,2 require accurate veriﬁcation of treatment plans. Pretreat-

2.A | Linear accelerator and treatment planning
system

ment quality assurance (QA)3 considers point‐dose measurements

All measurements were performed at the Illawarra Cancer Care Cen-

performed with an ionization chamber4 and dose distribution mea-

tre (Wollongong, NSW, Australia) using a Varian Clinac® iX (Varian

surements performed with an electronic portal imaging device

Medical Systems, Palo Alto, CA, USA) linac equipped with a Millen-

(EPID),5–7 a phantom‐based electronic array8–11 or ﬁlms. However,

nium 120‐MLC with leaf width at the center of 5 mm. The linac

time‐consuming pretreatment QA is typically considered only once

operated with a pulse frequency of 360 Hz and was calibrated to

before the ﬁrst treatment session; potential changes or errors in all

deliver 1 cGy/MU at dmax in water, at 100 cm source‐to‐surface dis-

12,13

sessions will remain unaddressed and/or undetected.

tance (SSD). In all cases, a 6 MV ﬂattened photon beam was used.

An in vivo veriﬁcation approach validates, in real time, accuracy,

For all dose calculation with a TPS, and for all IMRT plans, we

and integrity of treatment plans; parameters monitored include, for

used the Pinnacle's adaptive convolution‐superposition (CS) algo-

instance, the output of a medical linear accelerator (linac) and the

rithm implemented into the Pinnacle3 TPS version 14 (Philips Medi-

position and/or movement of the leaves of a multileaf collimator

cal Systems, Eindhoven, the Netherlands). Dose calculations were

(MLC).12–15 Solutions for in vivo monitoring include16 the use of

performed with a grid of 2 mm. Also, clinical IMRT plans were cre-

transit and transmission detectors.

ated, within the TPS, based on computed tomography (CT) datasets

Transit detectors such as EPIDs are placed so that the beam

of the Solid Water phantom; a SOMATOM CT Scanner (Siemens

penetrates the patient ﬁrst, and then the detector.17–19 QA with

Healthineers, Erlangen, Germany), acquiring axial slices of 2 mm, was

transit EPIDs is challenging; their response is energy dependent and

used.

there is additional scatter from the patient; also, they are not able to
discriminate between changes in signal due to changes in ﬂuence
incident on the patient from changes in signal due to anatomical
variations within the patient.20

2.B | The MP512 system
The MP512 is a prototype of a monolithic silicon‐array detector; it

Transmission detectors are, instead, placed between the linac

was developed at the Centre for Medical Radiation Physics (Univer-

head and the patient. Commercially available options include the

sity of Wollongong, NSW, Australia). The prototype has 512 diode‐

Device for Advanced Veriﬁcation of IMRT Delivery (DAVID) system

sensitive volumes; these have an area of 0.5 × 0.5 mm2 and are uni-

(PTW, Freiburg, Germany), a ﬂat, multiwire transmission‐type ioniza-

formly distributed with a pitch of 2 mm over an active area of

tion chamber21,22; the Dolphin detector with the COMPASS soft-

52 × 52 mm2. The MP512 is operated in passive mode (i.e., no

ware (IBA Dosimetry, Germany), which uses 1513 air‐vented plane

external bias is applied); its associated readout electronics has a high

parallel ionization chambers,23–25 the integral quality monitoring

temporal resolution (pulse‐by‐pulse signal acquisition).32

(IQM) system (iRT Systems GmbH, Koblenz, Germany), a large‐area

In the literature, the MP512 has been characterized as a phan-

wedge ionization chamber12,13,26,27; the Delta4 Discover (ScandiDos

tom‐based detector for quality assurance in modern radiotherapy; it

AB, Uppsala, Sweden), a 2D solid‐state array.16 Several prototypes

was demonstrated to be an accurate dosimeter for the measurement

have also been proposed in the literature, including optical attenua-

of output factors, percentage depth dose distributions, and lateral‐

tion‐based scintillating ﬁbers ; 2D solid‐state arrays, such as the

dose proﬁles; furthermore, its angular dependence was investigated

MP12129,30 and the MP512.31

and corrected for, making it a suitable candidate for quality assur-

28

Transmission detectors allow for independent monitoring of the

ance in arc deliveries.33–35 The use of the MP512 as a transmission

output of a linac, and of the position and/or movement of the leaves

detector was also assessed.31 In that study, it was reported that the

of an MLC.16 However, they have limitations. Any device placed in

MP512 in TM increases the surface dose by <25% for a SDD in the

the beam path affects beam quality and introduces beam attenua-

range from 0.3 to 18 cm, and by <5% for SDD >18 cm.31 The trans-

12

tion,

and as such has to be modeled in the treatment planning sys-

tem (TPS).27 Also, transmission detectors may increase surface

mission factor, at dmax depth in Solid Water, 100 cm SSD, was in the
range from 1.020 to 0.997 for SDDs from 0.3 to 24 cm.31

dose16,23 and their efﬁcacy for beam monitoring is limited by their
shape, active area, and spatial resolution.
The present study introduces a novel technique for using a 2D
solid‐state array prototype, the MP512 (512 diode‐sensitive volumes,

2.C | Gafchromic™ EBT3 ﬁlms and Farmer
ionization chamber

2 mm spatial resolution). The MP512 was used in transmission mode

We considered measurements with Gafchromic™ EBT3 ﬁlms and

(TM) to verify dose maps at a depth of dmax in Solid Water. TM

with a Farmer NE2571 ionization chamber, performed under the

measurements were taken at different surface‐to‐detector distances

same experimental conditions.

(SDDs) in order to adjust the area at dmax where the dose map is calculated.

Films were scanned with an EPSON Expression 10000 XL
ﬂatbed scanner using a 48‐bit RGB and a resolution of 72 dpi. Films
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were pre‐ and post‐scanned (24 hrs after irradiation) six times maintaining a consistent orientation and using only the last three optical
density maps. Films were calibrated using absolute dose measurements with the Farmer chamber.36 Film analysis methodology was
the same as that used by Aldosari et al.37

2.D | Measurements in transmission mode and in
dose mode
The MP512's active area was made light‐tight using a black plastic
sheet of thickness 80 µm. An equalization procedure, performed
prior to all measurement, was used to address a nonuniformity in
the integral response of the MP512's sensitive volumes.38 Also, to
convert readings to absolute dose, the MP512 was calibrated using
measurements of response linearity with dose; those measurements

FIG. 2.
scale).

Use of the MP512 system in transmission mode (not to

were performed in jaws‐deﬁned ﬁelds of 10 × 10 cm2, at a depth of
dmax in Solid Water, 100 cm SSD. Delivered MUs were in the range

thickness 5 mm; the top slab had a small recess (or air gap),39 cen-

from 1 to 1000 MU, at a ﬁxed dose rate of 600 MU/min. The

tered on the axis of the MP512's active area, of thickness 0.5 mm.

Farmer chamber was used for the absolute dose measurements at a

The air gap was necessary to minimize, in small radiation ﬁelds,40 the

depth of dmax in Solid Water.36

number and size of corrections required to relate the MP512's read-

For TM measurements, the MP512 was sandwiched between

ings to dose.41

two protective slabs of PMMA of thickness 3 mm. To minimize the

TM and DM measurements were performed in jaws‐deﬁned sta-

resulting composite thickness, each slabs had an opening, centered

tic ﬁelds of 2 × 2 cm2, 3 × 3 cm2, 5 × 5 cm2, 8 × 8 cm2, and

on the axis of the MP512's active area, of 9.5 × 9.5 cm2 (Figure 1).

10 × 10 cm2, as deﬁned at 100 cm SSD, delivering 200 MU at

The MP512 was then lodged into a movable holder of PMMA; by

600 MU/min. All measurements were repeated three times to mini-

moving the holder, the SDD could be varied in the range from 0.3

mize random uncertainties and errors were calculated as one stan-

to 24 cm (Figure 2). The effective area (Aeff), at a depth of dmax in

dard deviation. In all ﬁelds, the ratio between DM measurements
and TM measurements, as a function of SDD, was ﬁt using the least

Solid Water, was deﬁned as a function of SDD as:

Aeff ¼ AMP512


SSD þ 1:5 2
;
SSD  SDD

square method.
(1)

with AMP512 the MP512's active area.
For dose mode (DM) measurements, the MP512 was placed at a

2.E | Dose calculations in static square ﬁelds and
IMRT ﬁelds

depth of dmax, in Solid Water on the treatment couch. In that case,

The response of the MP512 in TM was measured in static ﬁelds of

the MP512 was sandwiched between two slabs of PMMA of

1 × 1 cm2 and 4 × 4 cm2, at 4 and 24 cm SDD. In each of these

F I G . 1 . (Upper panel) A snapshot of the
active area of the MP512 and protective
PMMA slabs. (Lower panel) A schematic of
the packaging of the MP512 system, with
the MP512 active area proper, upper and
lower PMMA protective slabs, and the
PCB‐FR4 board on which the detector is
wire bounded for signal readout.
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ﬁelds, the response of the MP512 in DM at dmax was then calculated using the relationship between DM and TM measurements
derived as described in the previous section. Note that these ﬁelds
were not part of those used to obtain the relationship in the ﬁrst
place. As the ﬁeld of 1 × 1 cm2 was smaller than the smallest ﬁeld
used for the ﬁt, the calculated response in DM was extrapolated.
The response in DM in the square ﬁeld of 4 × 4 cm2 was calculated
by interpolation. Calculated responses in DM were then compared
with responses in DM measured with the MP512 itself, with Gafchromic™ EBT3 ﬁlms and with a Farmer ionization chamber.
Additionally, the response of the MP512 in TM was measured at
4 and 24 cm SDD in clinical IMRT ﬁelds; these ﬁelds were delivered
with a treatment plan used to treat a malignant base of skull chor-

F I G . 3 . Central sensitive volume of the MP512: ratio of dose
mode measurements to transmission mode measurements as a
function of surface‐to‐detector distance, for all considered square
ﬁelds. Error bars did not exceed symbol size.

doma. The step‐and‐shoot plan, consisting of six static ﬁelds deﬁned
by the MLC, delivered a nominal dose 1.8 Gy per fraction to a gross
tumor volume (GTV) of 12.40 cm3. All ﬁelds were delivered with the
gantry at 0° (incident beam perpendicular to the active area of the
MP512) to rule out angular dependence effects on the response.35,42

T A B L E 1 Central sensitive volume of the MP512: slope (M) and
axis intercept (BA0) of the ratio of dose mode measurements to
transmission mode measurements, for all considered square ﬁelds;
absolute values.

Equivalent square ﬁelds (Aeq) of IMRT ﬁelds were calculated using43:
Aeq ¼

2xy
xþy

(2)

As above, in each of these ﬁelds, the response of the MP512 in DM

Square ﬁeld, side [cm]
Parameter

2

3

5

8

10

M

0.020

0.021

0.018

0.019

0.020

BAo

1.165

1.144

1.028

0.969

0.953

at dmax was then calculated using the relationship between DM and TM
measurements. Calculated dose distributions were compared with TPS
calculations and with DM measurements with the MP512 itself and

1.20

with Gafchromic™ EBT3 ﬁlms. The comparison was performed with a
gamma index analysis with the following acceptance criteria: 1%/1 mm,

1.10
BAo

2%/2 mm, and 3%/3 mm; a global threshold of 10% was applied.

1.00

3 | RESULTS

0.90

3.A | Measurements in transmission mode and in
dose mode
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Figure 3 shows ratios between DM and TM measurements with the
central sensitive volume of the MP512. Ratios, a function of ﬁeld
size and SDD, were ﬁt; corresponding slopes (M) and axis intercepts

F I G . 4 . Ratio of measurements in dose mode at dmax to
measurements in transmission mode: BAo as a function of radiation
ﬁeld area A. Error bars did not exceed symbol size.

(BA0) are in Table 1. It was observed that M depends weakly on ﬁeld
size. Based on this result, it was chosen to work with its value averaged across all considered ﬁelds. Also, to compute M and BA0, we
operated on the central sensitive volume ﬁrst; we then repeated the
procedure for all other sensitive volumes — all volumes had values
of M and BA0 in agreement to within 1.79%.
Using the averaged M (0.0196) and the BA0 value corresponding
to any given ﬁeld size, the dose in DM at dmax was calculated using

BAo ¼ 0:000142  A2  0:002392  A þ 1:176743;

(4)

for 0 cm2 ≤ A ≤ 25 cm2, and
BAo ¼ 0:000015  A2  0:002822  A þ 1:089544;

(5)

for 25 cm2 ≤ A ≤ 100 cm2.

the TM measurement at a given SDD as:
DM ¼ TMSDD  ðBA0  M  SDDÞ

(3)

For an arbitrary radiation ﬁeld of area A, BA0 could be found
from the piecewise polynomial ﬁt (adjusted regression coefﬁcient
2

R = 1) (Figure 4):

3.B | Dose calculations in regular static ﬁelds and
IMRT ﬁelds
BA0 values relative to static ﬁelds of 1 × 1 cm2 and 4 × 4 cm2 side,
and to IMRT ﬁelds, were calculated using Equations 4 and 5.
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Table 2 shows calculated dose at dmax (using TM measurements
at 4 and 24 cm SDD) along with corresponding TPS calculations and

using acceptance criteria of 3%/3 mm, 2%/2 mm, and 1%/1 mm,
respectively.
In the clinical practice, dose distributions are typically compared

DM measurements performed with the MP512 itself, with Gafchromic™ EBT3 ﬁlms, and with a Farmer ionization chamber.

ET AL.

using gamma index analysis,44–46 with a clinically signiﬁcant accep-

Table 3 shows gamma passing rates (%GP) between calculated

tance criterion of a 3% dose difference (%DD) and 3 mm distance‐

dose distributions for IMRT ﬁelds at dmax (using TM measurements

to‐agreement (DTA).1,47,48 In the present study, more stringent crite-

at 4 and 24 cm SDD) and corresponding TPS calculations and DM

ria were also considered for completeness. Our dose calculations

measurements performed with the MP512 itself and Gafchromic™

had signiﬁcantly lower %GP when considering a 1%/1 mm accep-

EBT3 ﬁlms.

tance criterion. This result can be explained by factors such as submillimeter misalignments in TM detector positioning, dose averaging
in TPS calculations over a 2 mm grid, noise artifacts created by ﬁlm

4 | DISCUSSION

heterogeneities, as well as handling and scanning procedures.
Misleading results from the gamma index analysis may also originate

A relationship was derived (Equation 3) for calculating dose, at a

from the use of detectors with a resolution not appropriate for the

depth of dmax, by using TM measurements with the MP512 at a

selected acceptance criterion.49 The use of a 2D solid‐state detector

given SDD, in any given ﬁeld. The relationship was used to calculate

prototype in TM with a higher resolution than the MP512, such as

dose at dmax by using TM measurements, at 4 and 24 cm SSD, in

the Octa (0.3 mm),50,51 would help to shed light.

static ﬁelds of 1 × 1 cm

and 4 × 4 cm . Calculations agreed to

Note that, in the present study, the MP512 was not modeled

within ±2.36% (mean difference 1.43%) with TPS calculations and

into the TPS. Its transmission factor was reported to be in the range

DM measurements performed with the MP512 itself, with Gafchro-

from 1.020 to 0.997 for SDDs from 0.3 to 24 cm.31 However, if

mic™ EBT3 ﬁlms, and with a Farmer ionization chamber.

clinical use will be considered, it is suggested that transmission fac-

2

2

The relationship was also used to calculate dose at dmax by using

tor has to be adequately incorporated into a TPS.12

TM measurements, at 4–24 cm SSD, in step‐and‐shoot clinical IMRT

The effective area, at a depth of dmax in Solid Water (Equation

ﬁelds. Calculated dose maps had %GP, when compared with TPS cal-

1), in which dose maps could be calculated based on TM measure-

culations and ﬁlm dosimetry, greater than 96.89%, 90.50%, 62.20%

ments varied in the range from 28 cm2 (SDD 0.3 cm) to 48.2 cm2

(SDD 4 cm) and greater than 97.22%, 93.80%, 59.00% (SDD 24 cm),

(SDD 24 cm); those values reﬂected a MP512 having an active area
of 27.04 cm2. Depending on the clinical application, a 2D detector
of larger active area may be required.

T A B L E 2 Static square ﬁeld of 1 and 4 cm side: calculated dose
[Gy] at dmax (using transmission mode measurements at 4 and 24 cm
SDD) compared with treatment planning system (TPS) calculations
and dose mode measurements performed with the MP512, with
ﬁlms and with a Farmer ionization chamber.

Using the MP512 in TM lodged on a holder positioned away
from the linac head has the additional advantage of minimizing the
contribution of scattered electrons, so that the detector response is
mostly driven by the photon energy ﬂuence, potentially simplifying
3D dose reconstructions at dmax in phantom.

MP512, calc.

Square
ﬁeld, side
[cm]

4 cm
SDD

24 cm
SDD

MP512,
meas.

TPS

EBT3

Farmer
chamber

1

0.798

0.821

0.816

0.810

0.809

0.813

for both jaws‐deﬁned and MLC‐deﬁned ﬁelds, also neglecting the

4

1.013

1.020

1.004

0.996

0.998

1.010

inﬂuence of the backup jaws.

Our study, a preliminary investigation, had the limitations of considering only 6 MV ﬂattened photon beams, of not assessing the
DM to TM ratio in ﬁelds off‐axis, and of using a unique BA0 value

T A B L E 3 Intensity‐modulated radiotherapy ﬁelds: gamma evaluation for dose calculations at dmax (using transmission mode measurements at
4 and 24 cm SDD) and corresponding treatment planning system calculations and dose mode measurements performed with the MP512 and
with ﬁlms.
Acceptance criteria
3%/3 mm

2%/2 mm

SDD
[cm]

MP512,
calc. vs.
TPS

MP512,
calc. vs.
EBT3

4

98.14%

24

97.22%

1%/1 mm

MP512, calc. vs.
MP512, meas.

MP512,
calc. vs.
TPS

MP512,
calc. vs.
EBT3

MP512, calc. vs.
MP512, meas.

MP512,
calc. vs.
TPS

MP512,
calc. vs.
EBT3

MP512, calc.
vs. MP512,
meas.

96.89%

99.79%

90.50%

92.00%

98.59%

62.20%

69.40%

99.40%

97.53%

99.69%

93.80%

93.80%

97.69%

59.00%

71.00%

99.00%

UTITSARN
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5 | CONCLUSION
The introduced technique uses a variable SDD for transmission
mode (TM) measurements with a 2D detector. In this way, dose
maps at a depth of dmax in Solid Water are calculated in an effective
area (Aeff) tailored to the size of the monitored target.
When considering a gamma index analysis with a strict 1%/1 mm
acceptance criterion, lower gamma passing rates (%GP) between our
dose calculations and benchmarks (treatment planning system calculations, ﬁlm dosimetry), which can be due to submillimeter misalignments in detector positioning or dose averaging in calculations,
emphasize the importance of developing array detectors with high‐
spatial resolution.
This study represents a ﬁrst step in the development of a real‐
time high‐resolution 3D dose reconstruction technique based on TM
measurements with the MP512 prototype.
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